Epigenetic Reprogramming in Cancer
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The demonstration of induced pluripotency and direct lineage conversion has led to remarkable insights regarding the roles of transcription factors and chromatin regulators in mediating cell state transitions. Beyond its considerable implications for regenerative medicine, this body of work is highly relevant to multiple stages of oncogenesis, from the initial cellular transformation to the hierarchical organization of established malignancies. Here, we review conceptual parallels between the respective biological phenomena, highlighting important interrelationships among transcription factors, chromatin regulators, and preexisting epigenetic states. The shared mechanisms provide insights into oncogenic transformation, tumor heterogeneity, and cancer stem cell models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [117]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Expression of a single transfected cDNA converts fibroblasts to myoblasts
Davis, R. L., Weintraub, H., & Lassar, A. B. (1987) · Cell · doi:10.1016/0092-8674(87)90585-x · Cited by 3,385
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Cited by
Items 301–400 of 702
Insights from pharmacological similarity of epigenetic targets in epipolypharmacology
Naveja, J. J., & Medina‐Franco, J. L. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.006 · Cited by 33
Liu, P., Zhang, J., Du, D., Zhang, D., Jin, Z., Qiu, W., Zhou, X., Dong, S., Zhou, M., Zhao, H., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01110-9 · Cited by 34
“Numerous recent studies have shown that altered epigenetic regulations, such as DNA methylation, are associated with the development of tumors [13], metabolic diseases [14] and autoimmune disorders [15].”
BackgroundCrosstalk Between DNA Methylation and Gene Mutations in Colorectal Cancer
Dobre, M., Salvi, A., Pelisenco, I. A., Vasilescu, F., Petro, G. D., Herlea, V., & Milanesi, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.697409 · Cited by 36
“Epigenetic aberrations are reversible and therefore represent promising targets for novel approaches for cancer therapies (41, 42).”
BackgroundHuyghe, A., Furlan, G., Schröder, J., Bachelard-Cascales, É., Trajkova, A., Ruel, M., Stüder, F., Larcombe, M. R., Sun, Y., Mugnier, F., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00986-w · Cited by 38
Nawaz, I., Qiu, X., Wu, H., Yang, L., Fan, Y., Hu, L., Zhou, Q., & Ernberg, I. T. (2014) · Epigenetics · doi:10.4161/epi.29499 · Cited by 34
Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer
Menéndez, J. A., & Alarcón, T. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00049 · Cited by 34
“…merely reflect the shared roles of transcription factors and chromatin regulators in mediating cell state transitions, which correspondingly occur during induced pluripotency and during the conversion of differentiated cells into a tumorigenic state (Suvà et al., 2013; Tung and Knoepfler, 2015).”
BackgroundDing, W., Feng, G., Hu, Y., Chen, G., & Shi, T. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00020 · Cited by 33
Long, W., Zhao, W., Ning, B., Huang, J., Chu, J., Li, L., Ma, Q., Xing, C., Wang, H. Y., Liu, Q., et al. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy007 · Cited by 32
“the cancer initiating cells in disease progression, relapse, and poor outcomes (Suva et al., 2013).”
BackgroundLiu, Z., Sun, J., Li, C., Xu, L., & Liu, J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08185-w · Cited by 31
“Discussion The alteration of epigenetic machineries such as histone methylations has been identified as essential mechanisms driving initiation and progression of human cancers including the hepatocellular carcinoma [18, 20].”
BackgroundKDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7/CCNE1 axis
Chen, B., Chen, H., Lü, S., Zhu, X., Que, Y., Zhang, Y., Huang, J., Zhang, L., Zhang, Y., Sun, F., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04800-1 · Cited by 31
“It has been known that H3K4me3 at the promoter area is a marker of transcriptional activation [44].”
BackgroundShteinfer‐Kuzmine, A., Verma, A., Arif, T., Aizenberg, O., Paul, A., & Shoshan‐Barmatz, V. (2020) · IUBMB Life · doi:10.1002/iub.2407 · Cited by 34
Epigenetic plasticity, selection, and tumorigenesis
Flavahan, W. A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191215 · Cited by 32
The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic Link
Amsalem, Z., Arif, T., Shteinfer‐Kuzmine, A., Caspi, V. C., & Shoshan‐Barmatz, V. (2020) · Cancers · doi:10.3390/cancers12041031 · Cited by 37
“Interplay between metabolism and epigenetics [4,5,7–9,12,13,17–19,30] is now considered an enabling characteristic of cancer [4,31,32].”
BackgroundInhibition of H3K4me2 Demethylation Protects Auditory Hair Cells from Neomycin-Induced Apoptosis
He, Y., Yu, H., Cai, C., Sun, S., Chai, R., & Li, H. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8841-3 · Cited by 32
Simithy, J., Sidoli, S., & Garcia, B. A. (2018) · PROTEOMICS · doi:10.1002/pmic.201700309 · Cited by 34
The evolving cancer stem cell paradigm: Implications in veterinary oncology
Pang, L. Y., & Argyle, D. J. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2014.12.029 · Cited by 31
Profiling of Epigenetic Features in Clinical Samples Reveals Novel Widespread Changes in Cancer
Noberini, R., Restellini, C., Savoia, E. O., Raimondi, F., Ghiani, L., Jodice, M. G., Bertalot, G., Bonizzi, G., Capra, M. C., Maffini, F. A., et al. (2019) · Cancers · doi:10.3390/cancers11050723 · Cited by 32
Liu, W., & Irudayaraj, J. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111358 · Cited by 31
Fernandez, T. D. S., Fernandez, C. D. S., & Mencalha, A. L. (2013) · BioMed Research International · doi:10.1155/2013/430290 · Cited by 34
“So, the hiPSCs are highly relevant to study the multiple stages of oncogenesis, from the initial cellular transformation to the hierarchical organization of established malignancies providing a human cell model to study the stages of disease [59, 60].”
BackgroundLats2 is critical for the pluripotency and proper differentiation of stem cells
Aylon, Y., Sarver, A. L., Tovy, A., Ainbinder, E., & Oren, M. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2013.188 · Cited by 34
“Deregulation of genes important for maintaining stemness is also invariably implicated in cancer.(7) In fact, oncogenic transformation often hijacks and distorts developmental transcriptional wiring.”
BackgroundWang, L., Lin, Y.-L., Li, B., Wang, Y.-Z., Li, W., & Ma, J. (2014) · Journal of International Medical Research · doi:10.1177/0300060514540631 · Cited by 29
“Previous studies have described the importance of DNA methylation in human cancers, with aberrant DNA methylation in the promoter regions of tumour suppressor genes at cytosine-phosphate-guanine islands being recognized as one of the hallmarks of human cancers, and associated with the downregulation of gene expression…”
BackgroundSpatial promoter–enhancer hubs in cancer: organization, regulation, and function
Zhao, J., & Faryabi, R. B. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.07.017 · Cited by 28
Kogan, A. A., Lapidus, R. G., Baer, M. R., & Rassool, F. V. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.005 · Cited by 29
Selective Targeting of Cancer Signaling Pathways with Nanomedicines: Challenges and Progress
Barkat, H. A., Das, S. S., Barkat, M. A., Beg, S., & Hadi, H. A. (2020) · Future Oncology · doi:10.2217/fon-2020-0198 · Cited by 30
The Epigenetics of Glioma Stem Cells: A Brief Overview
Valor, L. M., & Hervás-Corpión, I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.602378 · Cited by 28
“Epigenetic mechanisms contribute to the cellular hierarchy of tumoral tissue in GB (7) and are crucial to understanding tumorigenesis and response to treatment in gliomas.”
BackgroundLineage Plasticity in Cancer: The Tale of a Skin-Walker
Thankamony, A. P., Subbalakshmi, A. R., Jolly, M. K., & Nair, R. (2021) · Cancers · doi:10.3390/cancers13143602 · Cited by 31
Luo, Z., Li, Z.-G., Gui, S.-L., Chi, B., & Ma, J. (2013) · Journal of International Medical Research · doi:10.1177/0300060513504705 · Cited by 28
Enhancing the Efficacy of Radiation Therapy: Premises, Promises, and Practicality
Coleman, C. N., Lawrence, T. S., & Kirsch, D. G. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3865 · Cited by 29
Revelations About Aging and Disease from Unconventional Vertebrate Model Organisms
Zhao, Y., Seluanov, A., & Gorbunova, V. A. (2021) · Annual Review of Genetics · doi:10.1146/annurev-genet-071719-021009 · Cited by 32
Li, D., Bi, F., Cao, J.-M., Cao, C., Li, C., Liu, B., & Yang, Q. F. (2013) · Oncotarget · doi:10.18632/oncotarget.1549 · Cited by 27
“Promoter methylation, with concurrent changes in histone modifications, is an epigenetic phenomenon which can affect the conformation of chromatin and the accessibility of DNA for transcription factors [9,10].”
Lee, S., Lee, C., Hwang, C. Y., Kim, D., Han, Y.-H., Hong, S. N., Kim, S., & Cho, K. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0450 · Cited by 29
Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies
Yan, H., Tian, S., Slager, S. L., Sun, Z., & Ördög, T. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwv187 · Cited by 27
“Chromatin regulators, which often play roles in cancer as oncogenes or tumor suppressors (68), are frequently mutated (63, 69), translocated (65), or aberrantly expressed (33, 59) in various diseases.”
BackgroundBever, K. M., Thomas, D. L., Zhang, J., Rivera, E. A. D., Rosner, G. L., Zhu, Q., Nauroth, J. M., Christmas, B. J., Thompson, E. D., Anders, R. A., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01014-8 · Cited by 29
Targeting epigenetic alterations in cancer stem cells
Verona, F., Pantina, V. D., Modica, C., Lo Iacono, M., D’Accardo, C., Porcelli, G., Cricchio, D., Turdo, A., Gaggianesi, M., Franco, S. D., et al. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1011882 · Cited by 30
“To support these data, it was demonstrated that during the cellular differentiation, stem cells (SCs) lose H3K4me3 mark and acquire a compact chromatin profile (Suva et al., 2013; Yamazaki et al., 2013).”
Ge, Y., Xu, L., Jia, R.-P., Xu, Z., Feng, Y., Wu, R., Peng, Y., Zhao, Y., Gui, Z.-L., Tan, S., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-1515-3 · Cited by 26
“DNA methylation of CpG islands within the promoter region of genes is an alternative mechanism of gene inactivation to gene deletion or mutation and is frequently involved in the development and progression of many types of cancer, including PCa [5, 6].”
BackgroundKar, S., & Patra, S. K. (2017) · Gene · doi:10.1016/j.gene.2017.11.077 · Cited by 30
An Epigenetic Mechanism Underlying Doxorubicin Induced EMT in the Human BGC-823 Gastric Cancer Cell
Han, R., Ji, X., Dong, X., Xiao, R., Liu, Y.-P., Xiong, J., & Zhang, Q. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.10.4271 · Cited by 29
“Together, our data suggested that an epigenetic mechanism was involved in the maintenance of EMT in ltDSCs. Histone acetylation is one of the epigenetic mechanisms in regulating gene expression (Suva et al., 2013).”
BackgroundLi, D., Bi, F., Chen, N., Cao, J.-M., Sun, W., Zhou, Y., Cao, C., Li, C., & Yang, Q. F. (2014) · Oncotarget · doi:10.18632/oncotarget.1800 · Cited by 25
“Promoter methylation, with concurrent changes in histone modifications, is an epigenetic phenomenon that can affect the conformation of chromatin and tissuespecific gene expression[23,24].”
BackgroundPerner, F., & Armstrong, S. A. (2020) · Cells · doi:10.3390/cells9122721 · Cited by 26
Cell-autonomous heterogeneity of nutrient uptake in white adipose tissue of rhesus macaques
Varlamov, O., Chu, M., Cornea, A., Sampath, H., & Roberts, C. T. (2015) · Endocrinology · doi:10.1210/en.2014-1699 · Cited by 25
“Alternatively, these differences may represent epigenetic reprogramming triggered by the local environment, as documented for tumor and adipocyte heterogeneity (19, 55).”
BackgroundSMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis
Yu, P.-C., Hou, D., Chang, B., Liu, N., Xu, C., Chen, X., Hu, C.-L., Liu, T., Wang, X., Zhang, Q., et al. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.04.023 · Cited by 28
Wang, Z., Yang, X., Guo, S., Yang, Y., Su, X., Shen, Y., & Long, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562314 · Cited by 24
“Interphase heterochromatin forms functional domains and networks with the help of various transcriptional factors and can undergo macromolecular crowding (1, 3, 4).”
BackgroundCinghu, S., Yellaboina, S., Freudenberg, J., Ghosh, S., Zheng, X., Oldfield, A., Lackford, B. L., Zaykin, D. V., Hu, G., & Jothi, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318598111 · Cited by 26
“ESCs can self-renew indefinitely and can differentiate into all derivatives of the three germ layers, making them an attractive model for regenerative medicine and disease modeling (15 – 17).”
Watanabe, F., Hollingsworth, E. W., Bartley, J. M., Wisehart, L., Desai, R., Hartlaub, A. M., Hester, M. E., Schiapparelli, P. V., Quiñones‐Hinojosa, A., & Imitola, J. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae051 · Cited by 29
Demethylation of the Human Eotaxin-3 Gene Promoter Leads to the Elevated Expression of Eotaxin-3
Lim, E. J., & Rothenberg, M. E. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302454 · Cited by 27
“tors at proximal and distal regulatory elements, driving epigenetic programs involved in cellular proliferation, apoptosis, differentiation, and DNA stability (19).”
BackgroundIntegrin α9 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma
Nawaz, I., Hu, L., Du, Z., Moumad, K., Ignatyev, I., Pavlova, T. V., Kashuba, V. I., Almgren, M., Zabarovsky, E. R., & Ernberg, I. T. (2015) · Oncotarget · doi:10.18632/oncotarget.5154 · Cited by 24
“Changes in DNA methylation play an important role in both normal development and differentiation as well as cancer and several other diseases [13].”
BackgroundMatsuda, Y., Ishiwata, T., Yoshimura, H., Yamashita, S., Ushijima, T., & Arai, T. (2015) · Pancreas · doi:10.1097/mpa.0000000000000427 · Cited by 24
“DNA methylation is a major mechanism for regulating various cell functions, including metastasis(26) and stemness.(27) Boulland et al(28) previously showed that nestin expression in adipose tissue stem cells is regulated by methylation.”
BackgroundMethylation‐associated miR‐193b silencing activates master drivers of aggressive prostate cancer
Mazzu, Y. Z., Yoshikawa, Y., Nandakumar, S., Chakraborty, G., Armenia, J., Jehane, L. E., Lee, G. M., & Kantoff, P. W. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12536 · Cited by 26
“Epigenetic mechanisms of gene expression regulation, including DNA methylation, histone modifications, and small noncoding microRNA (miRNA), play critical roles in cancer initiation and progression (Suva et al., 2013).”
BackgroundCurrent discovery strategies for hepatocellular carcinoma therapeutics
Dai, Q., Zhang, C., Yuan, Z., Sun, Q., & Jiang, Y. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696769 · Cited by 26
“ome level without involving changes of the DNA sequence [99].”
BackgroundBivalent chromatin: a developmental balancing act tipped in cancer
Glancy, E., Choy, N., & Eckersley-Maslin, M. A. (2024) · Biochemical Society Transactions · doi:10.1042/bst20230426 · Cited by 27
Enhancer-promoter hubs organize transcriptional networks promoting oncogenesis and drug resistance
Perlman, B. S., Burget, N. G., Zhou, Y., Schwartz, G. W., Petrovic, J., Modrusan, Z. D., & Faryabi, R. B. (2024) · Nature Communications · doi:10.1038/s41467-024-52375-6 · Cited by 29
C1Q+ TPP1+ macrophages promote colon cancer progression through SETD8-driven p53 methylation
Veschi, V., Verona, F., Bella, S. D., Turdo, A., Gaggianesi, M., Franco, S. D., Mangiapane, L. R., Modica, C., Iacono, M. L., Bianca, P., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02293-y · Cited by 26
“Epigenetic regulators are known to significantly affect epigenetic reprogramming of cancer stem cells (CSCs) [16].”
Mechanisms underlying the formation of induced pluripotent stem cells
Gonzãlez, F., & Huangfu, D. (2015) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.206 · Cited by 27
Nuclear Reprogramming by Defined Factors: Quantity Versus Quality
Sebban, S., & Buganim, Y. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.08.006 · Cited by 24
Bhattacharya, R., Brown, J. S., Gatenby, R. A., & Ibrahim‐Hashim, A. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.06.003 · Cited by 29
Reprogramming cancer cells: A novel approach for cancer therapy or a tool for disease-modeling?
Yılmazer, A., de Lázaro, I., & Taheri, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.027 · Cited by 27
“As a result, cancer cells regulate their epigenetic circuits to rewire their differentiation status and thus refuel cancer growth [56].”
BackgroundExploiting tumor epigenetics to improve oncolytic virotherapy
Forbes, N. E., Abdelbary, H., Lupien, M., Bell, J. C., & Diallo, J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00184 · Cited by 25
“As discussed previously, epigenetic reprogramming is well known to play an important role in oncogenic transformation and numerous reviews extensively cover the role of epigenetics in cancer (Muntean and Hess, 2009; Baylin and Jones, 2011; Hatziapostolou and Iliopoulos, 2011; Suva et al., 2013).”
BackgroundOrzol, P., Nekulová, M., Holčáková, J., Müller, P., Votesek, B., & Coates, P. J. (2016) · Tumor Biology · doi:10.1007/s13277-016-4880-x · Cited by 23
“Taken together, these data indicate thatΔNp63 is insufficient to allow full EMT, which is due to global remodeling/reprogramming of the genome [42, 43], and in these breast cancer cells is more involved in epithelial lineage determination (basal versus luminal) than in epithelial-mesenchymal lineage determination.”
BackgroundReticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 26
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review)
Barbaro, A. D. L., Perletti, G., Bonapace, I. M., & Monti, E. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2490 · Cited by 24
“Epigenetic alterations are now recognized to be a driving force of the processes at all steps of carcinogenesis (53).”
BackgroundDifferentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor
Carpentieri, A., Cozzoli, E., Scimeca, M., Bonanno, E., Sardanelli, A. M., & Gambacurta, A. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.244 · Cited by 22
“also clarify the mechanisms that underlie oncogenic transformation.(4,5) Thus reprogramming and oncogenic trans-”
BackgroundTang, D., Lin, Q., He, Y., Chai, R., & Li, H. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00039 · Cited by 22
“Epigenetic modifications have recently been reported to play important roles in cell development, survival, proliferation, and regeneration (Weaver et al., 2004; Stewart et al., 2009; Suvà et al., 2013; Roidl and Hacker, 2014).”
BackgroundThe cancer paradigms of mammalian regeneration: can mammals regenerate as amphibians?
Sarig, R., & Tzahor, E. (2017) · Carcinogenesis · doi:10.1093/carcin/bgw103 · Cited by 24
Loeffler‐Wirth, H., Binder, H., Willscher, E., Gerber, T., & Kunz, M. (2018) · Biology · doi:10.3390/biology7020023 · Cited by 24
“that these genes act as potential regulators for fate decisions ensuring the developmental plasticity and pluripotency of developing tumor cells in agreement with concepts of epigenetic mechanisms of tumor development [15,16].”
BackgroundNanoscopic subcellular imaging enabled by ion beam tomography
Coskun, A. F., Han, G., Ganesh, S., Chen, S.-Y., Rovira‐Clavé, X., Harmsen, S., Jiang, S., Schürch, C. M., Bai, Y., Hitzman, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20753-5 · Cited by 25
Huumonen, K., Korkalainen, M., Viluksela, M., Lahtinen, T., Naarala, J., & Juutilainen, J. (2014) · Frontiers in Public Health · doi:10.3389/fpubh.2014.00139 · Cited by 27
Zahraeifard, S., Xiao, Z., So, J. Y., Ahad, A., Montoya, S., Park, W. Y., Sornapudi, T., Andohkow, T., Read, A., Kedei, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50262-8 · Cited by 27
Epigenetic regulation of cancer stem cell and tumorigenesis
Zhu, K., Xie, V. K., & Huang, S. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.001 · Cited by 22
High SOX9 Maintains Glioma Stem Cell Activity through a Regulatory Loop Involving STAT3 and PML
Aldaz, P., Martín-Martín, N., Saenz‐Antoñanzas, A., Carrasco‐García, E., Álvarez‐Satta, M., Elúa-Pinin, A., Pollard, S. M., Lawrie, C. H., Moreno‐Valladares, M., Samprón, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094511 · Cited by 24
“Transcription factors that govern stem cell differentiation can potentially function as oncogenes by promoting the acquisition of transcriptional programs required for tumorigenesis, including epigenetic dysregulation [12].”
BackgroundKonishi, I., Abiko, K., Hayashi, T., Yamanoi, K., Murakami, R., Yamaguchi, K. D., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2022) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2022.33.e83 · Cited by 24
“In addition, it has recently been hypothesized that epigenetic reprogramming precedes to various genetic or chromosomal alterations as the earliest step of carcinogenesis [83-85].”
BackgroundEpigenetic mechanisms of tumorigenicity manifesting in stem cells
Tung, P. X., & Knoepfler, P. S. (2014) · Oncogene · doi:10.1038/onc.2014.172 · Cited by 24
“This hypothesis is based on the fact that iPSC reprogramming and tumorigenesis share striking molecular similarities at multiple stages of oncogenesis, from the initial oncogenic transformation to the development of an actual complex tumor (17, 18).”
BackgroundApplication of recombinant TAF3 PHD domain instead of anti-H3K4me3 antibody
Kungulovski, G., Mauser, R., Reinhardt, R., & Jeltsch, A. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0061-9 · Cited by 23
Cancer epigenetics in solid organ tumours: A primer for surgical oncologists
Drake, T. M., & Søreide, K. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.02.005 · Cited by 25
Lei, J. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110196 · Cited by 31
“Accumulation of undesirable epigenetic changes may result in promoting or causing diseases [17, 18, 36, 43, 59, 60, 70, 72, 81, 92].”
BackgroundDesign and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors
Gehling, V. S., McGrath, J. P., Duplessis, M., Khanna, A., Brucelle, F., Vaswani, R. G., Côté, A., Stuckey, J. I., Watson, V. G., Cummings, R. T., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00060 · Cited by 23
Huang, Z., Li, B., Guo, Y. H., Wu, L., Kou, F., & Yang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.723172 · Cited by 22
“DNA methylation (MET) is a form of epigenetic modification; MET may negatively influence transcription by impeding the induction of genes needed for epigenetic reprogramming (8, 9).”
BackgroundThe Stem Cell Division Theory of CancerPreprint
López‐Lázaro, M. (2017) · Preprints.org · doi:10.20944/preprints201707.0074.v1 · Cited by 21
Pawlak, A., Chybicka, K., Zioło, E., Strządała, L., & Kałas, W. (2022) · Cancers · doi:10.3390/cancers14061530 · Cited by 22
“Introduction It is generally accepted that, apart from genetic mutations in pro-oncogenes or tumor suppressor genes, epigenetic modifications may drive the oncogenic transformation [1,2].”
BackgroundChromatin remodeling factor LSH affects fumarate hydratase as a cancer driver
Liu, S., & Tao, Y. (2016) · 癌症:英文版 · doi:10.1186/s40880-016-0138-7 · Cited by 20
“a critical role in the development of several malignancies [15], but their role in the progress of NPC remains unknown.”
BackgroundHolmes, E. E., Goltz, D., Sailer, V. W., Jung, M., Meller, S., Uhl, B., Dietrich, J., Röhler, M., Ellinger, J., Kristiansen, G., et al. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0270-x · Cited by 20
Methylatedclaudin-11associated with metastasis and poor survival of colorectal cancer
Li, J., Zhou, C., Ni, S., Wang, S., Ni, C., Yang, P., & Ye, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21997 · Cited by 26
“Both genetic and epigenetic alterations in cancer result in de novo acquisition of developmental programs of cell with unlimited self-renewal potential [16].”
BackgroundThe many faces of cancer evolution
Ciriello, G., & Magnani, L. (2021) · iScience · doi:10.1016/j.isci.2021.102403 · Cited by 22
“, 2018) or even single cells (Gaiti et al., 2019; Klein et al., 2002; Suva et al., 2013) from the same tumor.”
BackgroundThe Prognostic Significance of Histone Demethylase UTX in Esophageal Squamous Cell Carcinoma
Li, S.-H., Lu, H., Huang, W., Tien, W.-Y., Lan, Y.-C., Lin, W.-C., Tsai, H., & Chen, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010297 · Cited by 19
De- and re-differentiation of the melanocytic lineage
Larribère, L., & Utikal, J. S. (2013) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.11.006 · Cited by 20
“p53 and INK4A/ARF), whose effects on proliferation and apoptosis restrain both reprogramming and transformation (Orkin and Hochedlinger, 2011; Suvà et al., 2013).”
BackgroundRijlaarsdam, M. A., van der Zwan, Y. G., Dorssers, L. C. J., & Looijenga, L. H. J. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-141 · Cited by 23
“DNA CpG methylation is routinely investigated on a genome wide scale [2,3].”
BackgroundJiang, X., Lim, C. Z. H., Li, Z., Lee, P. L., Yatim, S. M. J. M., Guan, P., Li, J., Zhou, J., Pan, J., Chng, W. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122983 · Cited by 21
“Because tumor initiating cells or cancer stem cells have been thought to have undergone epigenetic reprogramming [36, 37], we sought to determine if D9 as a histone methylation inhibitor would be effective in targeting AML leukemia stem cells (LSCs).”
BackgroundLemieux, S., Sargeant, T., Laperrière, D., Ismail, H., Boucher, G., Rozendaal, M. J., Lavallée, V., Ashton‐Beaucage, D., Wilhelm, B. T., Hébert, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx338 · Cited by 21
“Datasets 26 and 27 both correspond to the GNE cell line RNA-Seq dataset from Genentech (rpkm or variance-stabilized data) (18).”
MethodResultIntegrating RNA sequencing into neuro-oncology practice
Rogawski, D. S., Vitanza, N. A., Gauthier, A. C., Ramaswamy, V., & Koschmann, C. J. (2017) · Translational research · doi:10.1016/j.trsl.2017.06.013 · Cited by 22
“In addition, the heterogeneity of brain tumors may be fueled by epigenetic reprogramming of differentiated cancer cells back to CSCs, which is augmented in the presence of chemotherapy agents and microenvironmental factors like hypoxia.(109,110) Thus, treatments that target the reprogramming process could reduce tumor…”
BackgroundChen, X., Lin, Z., Xue, M., Si, J., & Chen, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133906 · Cited by 19
“Aberrant DNA methylation is an important epigenetic change and an early event in carcinogenesis[4].”
BackgroundChinaranagari, S., Sharma, P., Bowen, N. J., & Chaudhary, J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1804-1_7 · Cited by 20
Wang, Y., Lü, T., Sun, G., Zheng, Y., Yang, S., Zhang, H., Hao, S., Liu, Y., Ma, S., Zhang, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13411-y · Cited by 20
Kang, Y. (2018) · BioEssays · doi:10.1002/bies.201800058 · Cited by 20
Gliomas: a reflection of temporal gliogenic principles
Sojka, C., & Sloan, S. A. (2024) · Communications Biology · doi:10.1038/s42003-024-05833-2 · Cited by 19
“Likewise, neurodevelopmental TFs, such as ASCL1, POU3F2, SOX2, SALL2, and OLIG2 can act as oncogenes by inappropriately activating developmental programs that push differentiated GBM cells into tumor propagating GSCs 96,98,147 – 149 .”
BackgroundLuisier, R., Unterberger, E. B., Goodman, J. I., Schwarz, M., Moggs, J. G., Terranova, R., & van Nimwegen, E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1415 · Cited by 18
“Aberrant activity of transcription factors (TFs) is a hallmark of both human (1–3) and mouse (4) hepatocarcinogenesis and is considered as a key intrinsic regulatory mechanism underlying epigenetic reprograming associated with cancer development (5).”
BackgroundBröhm, A., Elsawy, H., Rathert, P., Kudithipudi, S., Schoch, T., Schuhmacher, M. K., Weirich, S., & Jeltsch, A. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.06.021 · Cited by 20
Xue, G., Lu, C., Pan, S., Zhang, Y., Miao, H., Shan, S., Zhu, X., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.17988 · Cited by 19
“Epigenetic processes are essential in normal development and differentiation but may be misdirected and predisposed to tumorigenesis [7].”
BackgroundGenetic evolution of keratinocytes to cutaneous squamous cell carcinoma
Tandukar, B., Deivendran, D., Chen, L., Bandari, A. K., Cruz‐Pacheco, N., Sharma, H., Wang, M., Xu, A., Chen, D. B., George, C. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65687-y · Cited by 19
Masuda, M., Wakasaki, T., & Toh, S. (2016) · PubMed · Cited by 19
Computational algorithms for in silico profiling of activating mutations in cancer
Jordan, E. J., Patil, K., Suresh, K., Park, J. H., Mossé, Y. P., Lemmon, M. A., & Radhakrishnan, R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03097-2 · Cited by 18
Intestinal Microbiota Influences DNA Methylome and Susceptibility to Colorectal Cancer
Zouggar, A., Haebe, J. R., & Benoit, Y. D. (2020) · Genes · doi:10.3390/genes11070808 · Cited by 17
Metadata
- Authors
- Suvà, M. L., Riggi, N., & Bernstein, B. E.
- Affiliations
- Broad Institute (US)
- Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
- Corresponding author
- Suvà, Mario L.
- Bernstein, Bradley E.
- Venue
- Science
- Published
- 2013-03-29
- Volume
- 339
- Issue
- 6127
- Pages
- 1567-1570
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3821556
- OpenAlex
- W2090757807
- Cited by
- 706
- References
- 64
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 19 · 2023: 40 · 2022: 34 · 2021: 61 · 2020: 62 · 2019: 48 · 2018: 58 · 2017: 72 · 2016: 67 · 2015: 76 · 2014: 85 · 2013: 43
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute of Environmental Health Sciences (U01ES017155)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic reprogramming, cancer, induced pluripotency, transcription factors, chromatin regulators, oncogenic transformation, tumor heterogeneity, cancer stem cells, cell state transitions
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Chromatin, Humans, Neoplasms, Transcription Factors, Neoplastic Stem Cells, DNA Methylation, Pluripotent Stem Cells, Epigenesis, Genetic, Mice, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.